Literature DB >> 407957

Neurofibromatosis: a neoplastic birth defect with two age peaks of severe problems.

V M Riccardi, B Kleiner.   

Abstract

A survey involving more than 400,000 patient sources revealed a population of 129 NFT patients relatively unbiased by the specific character of the disease (eg neurologic vs orthopedic problems), though biased in terms of severity. Two age peaks of severe disease were demononstrated, one early in life (10 yr or less) and one late (apex in 36- to 50-yr group). Neural crest-derived malignancies were the critical component of the second peak (75% of severe cases). The high burden nature of the disorder is emphasized by the fact that moderate and severe cases amounted to 64% in the survey population (ie those brought to medical attention) and 26% in nonproband affected family members in 46 families. In addition, even correcting for 5% of ascertainment of minimal-mild cases and 61% ascertainment of moderate-sever cases, 7% of the presumed NFT population may be considereed at risk for severe problems.

Entities:  

Mesh:

Year:  1977        PMID: 407957

Source DB:  PubMed          Journal:  Birth Defects Orig Artic Ser        ISSN: 0547-6844


  12 in total

Review 1.  MR imaging of abdominopelvic involvement in neurofibromatosis type 1: a review of 43 patients.

Authors:  T Thomas Zacharia; Diego Jaramillo; Tina Young Poussaint; Bruce Korf
Journal:  Pediatr Radiol       Date:  2004-10-27

2.  Testicular teratoma and peripheral neurofibromatosis.

Authors:  N Oakley; B Todd
Journal:  Postgrad Med J       Date:  1991-05       Impact factor: 2.401

3.  A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity.

Authors:  S M Huson; D A Compston; P Clark; P S Harper
Journal:  J Med Genet       Date:  1989-11       Impact factor: 6.318

4.  The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.

Authors:  Hilda A Crawford; Belinda Barton; Meredith J Wilson; Yemima Berman; Valerie J McKelvey-Martin; Patrick J Morrison; Kathryn N North
Journal:  J Genet Couns       Date:  2015-04-19       Impact factor: 2.537

5.  A genetic study of neurofibromatosis 1 in south-western Ontario. I. Population, familial segregation of phenotype, and molecular linkage.

Authors:  D I Rodenhiser; M B Coulter-Mackie; J H Jung; S M Singh
Journal:  J Med Genet       Date:  1991-11       Impact factor: 6.318

6.  Quality of Life in Adults with Neurofibromatosis 1 in Brazil.

Authors:  Natália Parenti Bicudo; Balduíno Ferreira de Menezes Neto; Lucimar Retto da Silva de Avó; Carla Maria Ramos Germano; Débora Gusmão Melo
Journal:  J Genet Couns       Date:  2016-03-05       Impact factor: 2.537

7.  The pathophysiology of neurofibromatosis. I. Resistance in vitro to 3-nitrotyrosine as an expression of the mutation.

Authors:  V M Riccardi; V A Maragos
Journal:  In Vitro       Date:  1980-08

8.  Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.

Authors:  Rosalie E Ferner; Mary Thomas; Gemma Mercer; Victoria Williams; Guy D Leschziner; Shazia K Afridi; John F Golding
Journal:  Health Qual Life Outcomes       Date:  2017-02-14       Impact factor: 3.186

9.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Authors:  Christina Bergqvist; Amandine Servy; Laurence Valeyrie-Allanore; Salah Ferkal; Patrick Combemale; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

10.  Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.

Authors:  Sheilagh Maguiness; Yemima Berman; Nathan Rubin; Melissa Dodds; Scott R Plotkin; Claire Wong; Christopher Moertel
Journal:  Neurology       Date:  2021-07-06       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.